<b><i>Introduction:</i></b> This study aimed to elucidate the coagulation disorders in non-ICU patients with acute kidney injury (AKI) and their contribution to clotting-related outcomes of intermittent kidney replacement therapy (KRT). <b><i>Methods:</i></b> We included non-ICU-admitted patients with AKI requiring intermittent KRT, clinically having a risk of bleeding and against systemic anticoagulant use during KRT between April and December 2018. The premature termination of treatment due to circuit clotting was considered a poor outcome. We analyzed the characteristics of thromboelastography (TEG)-derived and traditional coagulation parameters and explored the potential-affecting factors. <b><i>Results:</i></b> In total, 64 patients were enrolled. Hypocoagulability was detected in 4.7%–15.6% of patients by a combination of the traditional parameters, i.e., prothrombin time (PT)/international normalized ratio, activated partial PT, and fibrinogen. No patient had hypocoagulability observed on TEG-derived reaction time; only 2.1%, 3.1%, and 10.9% of patients had hypocoagulability on TEG-derived kinetic time (K-time), α-angle, and maximum amplitude (MA), respectively, which were also platelet-related coagulation parameters, despite 37.5% of the cohort having thrombocytopenia. In contrast, hypercoagulability was more prevalent, involving 12.5%, 43.8%, 21.9%, and 48.4% of patients on TEG K-time, α-angle, MA, and coagulation index (CI), respectively, although thrombocytosis was only in 1.5% of the cohort. Patients with thrombocytopenia showed lower fibrinogen level (2.6 vs. 4.0 g/L, <i>p</i> = 0.00), α-angle (63.5° vs. 73.3°, <i>p</i> = 0.00), MA (53.5 vs. 66.1 mm, <i>p</i> = 0.00), and CI (1.8 vs. 3.6, <i>p</i> = 0.00) but higher thrombin time (17.8 vs. 16.2 s, <i>p</i> = 0.00) and K-time (2.0 vs. 1.2 min, <i>p</i> = 0.00) than those with a platelet count over 100 × 10<sup>9</sup>/L. 41 patients were treated with heparin-free protocol, and 23 were treated with regional citrate anticoagulation (RCA). The premature termination rate was 41.5% on heparin-free patients, while 8.7% of patients underwent an RCA protocol (<i>p</i> = 0.006). Heparin-free protocol was the strongest adverse factor to poor outcomes. A heparin-free subgroup analysis found that the circuit clotting risk was increased by 61.7% with a 10 × 10<sup>9</sup>/L elevation in platelet count (odds ratio [OR] = 1.617, <i>p</i> = 0.049) and decreased by 67.5% following a second increase of PT (OR = 0.325, <i>p</i> = 0.041). No significant correlation was found between TEG parameters and premature circuit clotting. <b><i>Conclusions:</i></b> Most non-ICU-admitted patients with AKI had normal-to-enhanced hemostasis and activated platelet function based on TEG results, as well as a high rate of premature circuit clotting when receiving heparin-free protocol despite thrombocytopenia. Further studies are needed to better determine the use of TEG in respect to management of anticoagulation and bleeding complications in AKI patients with KRT.
